CHU Guadeloupe
- Address
- D106 Les Abymes, 97139 Les Abymes, France
CHU Guadeloupe - Hematology Research Center
CHU Guadeloupe is actively engaged in advanced clinical research focused on hematological disorders, with particular expertise in the treatment and management of sickle cell disease (SCD). The center participates in cutting-edge therapeutic trials aimed at addressing both the primary manifestations and complications of this inherited blood disorder, contributing valuable data to the global understanding of disease management in diverse patient populations.
- Anemia management in sickle cell disease patients
- Novel therapeutic interventions for sickle cell pain crises
- Evaluation of emerging pharmacological treatments for hemoglobinopathies
The research center demonstrates commitment to improving quality of life for patients suffering from sickle cell disease through rigorous evaluation of innovative treatments. Their participation in multi-phase clinical trials investigating agents like mitapivat reflects their dedication to advancing therapeutic options that target both the hematological and pain-related complications of SCD, ultimately seeking to reduce disease burden and improve patient outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Guadeloupe
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Mitapivat in Patients with Sickle Cell Disease: A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Multicenter Study | Agios Pharmaceuticals Inc. | Phase IV | Not Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amoxicillin | 1 | Unknown | 2023-10-26 | 2023-10-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.